Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


July 31, 2015 10:31 AM ET

Life Sciences Tools and Services

Company Overview of GVK Biosciences Private Limited

Company Overview

GVK Biosciences Private Limited provides contract research services to pharmaceutical and biotechnology companies. The company provides bioinformatics services, including DNA and protein sequence analysis, protein structure analysis, homology modeling, biostatistics, data analysis using SAS/R, and microarray data analysis; chemoinformatics services, including molecular modeling studies, lead generation, virtual screening, ADME and toxicological property prediction, and crystal structure prediction; structural biology services, including structure determination, critical analysis of protein structures, protein-drug interactions, and protein-protein interactions; and KPO and custom curation se...

Plot No. 28 A

IDA Nacharam

Hyderabad,  500076

India

Founded in 2000

Phone:

91 40 6692 9999

Fax:

91 40 6692 9900

Key Executives for GVK Biosciences Private Limited

Chief Executive Officer
Vice Chairman and Managing Director
Age: 51
Chief Financial Officer
Senior Vice President of Discovery Chemistry
Head of the Biology SBU & Collaborative Research initiatives
Compensation as of Fiscal Year 2015.

GVK Biosciences Private Limited Key Developments

GVK Biosciences May Exit Clinical Trials

GVK Biosciences Private Limited is considering putting its clinical trials business on the block, in part or full, if market buzz is to be believed. According to people familiar with the development, GVK Biosciences is already in parleys to sell the business, which accounts for just 10% of its revenues.

Medivir AB Announces Partnership with GVK Biosciences Private Ltd

Medivir AB has announced a partnership with GVK Biosciences Private Ltd., or GVK BIO. The new partnership is designed to deliver enhanced efficiency and quality within its portfolio of research projects while over time reducing overall research costs and enhancing future cost flexibility. To ensure that its operations are run as efficiently as possible, Medivir has conducted a review of its Discovery Research operations. While committed to maintaining the current size of its discovery portfolio to deliver a constant flow of candidate drugs into its development pipeline, it has identified the opportunity to improve quality and efficiency through partnership with GVK BIO. The partnership will consolidate and strengthen all current out-sourced synthetic chemistry in a single facility at GVK BIO's Integrated Discovery Research Campus, where an addition of approximately 20 scientific staff will further accelerate the synthesis and testing of compounds. The company has also decided to exit the neuropathic pain area, following adverse findings in non-clinical safety studies of MIV-247, its cathepsin S inhibitor being developed for neuropathic pain. Development of this program has been terminated and future drug discovery efforts will be focused in the core areas of oncology and infectious diseases. As a result of the changes described, around ten scientific staff at Medivir facilities in the UK and Sweden will be made redundant.

Medivir AB Enters into Partnership with GVK Biosciences Private Limited to Deliver Enhanced Efficiency and Quality within its Portfolio of Research Projects

Medivir AB announced that it has entered into a partnership with GVK Biosciences Private Ltd. to deliver enhanced efficiency and quality within its portfolio of research projects, reduce the overall research costs and enhance future cost flexibility. The partnership will consolidate and strengthen all current outsourced synthetic chemistry projects in a single facility at GVK BIO's integrated discovery research campus at Hyderabad, where an addition of approximately 20 scientific staff will further accelerate the synthesis and testing of compounds. Medivir also announced reorganization within its discovery research department, increasing its focus within the core areas of oncology and infectious diseases. The company has decided to exit the neuropathic pain area, following adverse findings in non-clinical safety studies of MIV-247, its Cathepsin S inhibitor being developed for neuropathic pain. The development of this program has been terminated and future drug discovery efforts will be focused in the core areas of oncology and infectious diseases.

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
November 6, 2014
Vanta Bioscience LC
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GVK Biosciences Private Limited, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.